Cargando…
P896: DEVELOPMENT AND VALIDATION OF A FRAILTY PREDICTION MODEL MORE SUITABLE FOR MULTIPLE MYELOMA IN CHINESE PATIENTS: THE TM FRAILTY SCORE.
Autores principales: | Chen, Y., Gu, J., Huang, B., Liu, J., Li, X., Li, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430115/ http://dx.doi.org/10.1097/01.HS9.0000846456.26633.e7 |
Ejemplares similares
-
Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score
por: Chen, Yadong, et al.
Publicado: (2023) -
P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022) -
Validating the agreement between the geriatric trauma frailty index and four published frailty scores in the Chinese geriatric trauma population
por: Zhao, Fangjie, et al.
Publicado: (2022) -
P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
por: Quach, H., et al.
Publicado: (2022) -
HAS FRAILTY SCORE AND FRAILTY LETHALITY CHANGED OVER TIME? HARMONIZATION OF NHANES COHORTS FROM 1999 TO 2016
por: Blodgett, Joanna M, et al.
Publicado: (2019)